These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31471390)

  • 1. Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells.
    Nukatsuka M; Saito H; Noguchi S; Takechi T
    In Vivo; 2019; 33(5):1439-1445. PubMed ID: 31471390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
    Yin G; Zeng B; Peng Z; Liu Y; Sun L; Liu C
    Oncol Rep; 2018 Mar; 39(3):1215-1226. PubMed ID: 29328488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
    Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
    Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
    Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
    Jia X; Li C; Li L; Liu X; Zhou L; Zhang W; Ni S; Lu Y; Chen L; Jeong LS; Yu J; Zhang Y; Zhang J; He S; Hu X; Sun H; Yu K; Liu G; Zhao H; Zhang Y; Jia L; Shao ZM
    Clin Cancer Res; 2019 Jun; 25(12):3658-3672. PubMed ID: 30833270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of estrogen receptor down-regulators for endocrine resistant breast cancer.
    Li Y; Orahoske CM; Urmetz SM; Zhang W; Huang Y; Gan C; Su B
    J Steroid Biochem Mol Biol; 2022 Nov; 224():106162. PubMed ID: 35932957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
    Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
    Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
    J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
    Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
    Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
    Kaminska K; Akrap N; Staaf J; Alves CL; Ehinger A; Ebbesson A; Hedenfalk I; Beumers L; Veerla S; Harbst K; Ehmsen S; Borgquist S; Borg Å; Pérez-Fidalgo A; Ditzel HJ; Bosch A; Honeth G
    Breast Cancer Res; 2021 Feb; 23(1):26. PubMed ID: 33602273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
    Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
    Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
    Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
    Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
    Uchiumi K; Tsuboi K; Sato N; Ito T; Hirakawa H; Niwa T; Yamaguchi Y; Hayashi SI
    Breast Cancer; 2019 Jul; 26(4):459-470. PubMed ID: 30610551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
    Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
    Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.